EOPM PT	O 1449/A and B (m	odifia	1 PT()/SB/08)	APPLICATION NO.:	10/595,230	ATTY. DOCKET NO.: C1271.70017US		
FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE				FILING DATE:	March 28, 2006	CONFIRMATION NO.: 5170		
	TEMENT BY			APPLICANT:	Kyle J. Lindstrom et al.			

U.S. PATENT DOCUMENTS

Examiner's	Cite	U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication or Issue	
Initials #	No.	Number	Kind Code	Document	of Cited Document MM-DD-YYYY	
		6,841,678	B2	Merli et al.	01-11-2005	
		6,852,861	B2	Merli et al.	02-08-2005	
		7,163,947	B2	Griesgraber et al.	01-16-2007	
		2002-0107262	A1	Lindstrom	08-08-2002	
		2003-0096835	A1	Crooks et al.	05-22-2003	
		2003-0144286	A1	Frenkel et al.	07-31-2003	
		2005-0085500	A1	Gutman et al.	04-21-2005	
		2005-0165236	A1	Colombo et al.	07-28-2005	
		2005-0245562	A1	Garcia-Echeverria et al.	11-03-2005	
		2009-0018122	A1	Lindstrom et al.	01-15-2009	

FOREIGN PATENT DOCUMENTS

Examiner's	Cita	Cite For	oreign Patent Document		Name of Patentee or Applicant of Cited	Date of Publication of	Translation
Initials #	No.	Office/ Country	Number	Kind Code	Document Document	Cited Document MM-DD-YYYY	(Y/N)
		WO	00/076519	A1	3M Innovative Properties Company	12-21-2000	
		WO	02/046193	A2	3M Innovative Properties Company	06-13-2002	
		WO	03/050121	A1	3M Innovative Properties Company	06-19-2003	
		WO	2004/058759	A1	3M Innovative Properties Company	07-15-2004	
		WO	2005/018551	A2	3M Innovative Properties Company	03-03-2005	
		WO	2005/018555	A2	3M Innovative Properties Company	03-03-2005	
		WO	2005/018556	A2	3M Innovative Properties Company	03-03-2005	
		WO	2005/032484	A3	3M Innovative Properties Company	04-14-2005	
		WO	2005/048933	A2	3M Innovative Properties Company	06-02-2005	
		WO	2005/048945	A2	3M Innovative Properties Company	06-02-2005	
		WO	2005/051317	A2	3M Innovative Properties Company	06-09-2005	
		WO	2005/051324	A2	3M Innovative Properties Company	06-09-2005	
		WO	2005/054237	A1	Novartis AG	06-16-2005	
		wo	2005/054238	A1	Novartis AG	06-16-2005	
		WO	2005/066169	A2	3M Innovative Properties Company	07-21-2005	
		WO	2005/066170	A1	3M Innovative Properties Company	07-21-2005	
		WO	2005/066172	A1	3M Innovative Properties Company	07-21-2005	
		WO	2005/076783	A2	3M Innovative Properties Company	08-25-2005	
		WO	2005/079195	A2	3M Innovative Properties Company	09-01-2005	

EXAMINE	:			DATE CONSI	DERED:		

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

EODW DTO	D-1449/A and B (m	odifia	+ PTO/SB/08)	APPLICATION NO.:	10/595,230	ATTY. DOCKET NO.:	C1271.70017US01
	RMATION I			FILING DATE:	March 28, 2006	CONFIRMATION NO.:	5170
	EMENT BY			APPLICANT:	Kyle J. Lindstrom	et al.	
				GROUP ART UNIT:	1625	EXAMINER:	Rita J. Desai
Sheet	2	of	2	GROUP ART UNIT.	1023	EXAMINER.	Kita J. Desai

wo	2005/094531	A2	3M Innovative Properties Company	10-13-2005
wo	2005/123079	A2	3M Innovative Properties Company	12-29-2005
wo	2005/123080	A2	3M Innovative Properties Company	12-29-2005
wo	2006/009826	A1	3M Innovative Properties Company	01-26-2006
WO	2006/009832	A1	3M Innovative Properties Company	01-26-2006
WO	2006/026760	A2	3M Innovative Properties Company	03-09-2006
wo	2006/028451	A1	3M Innovative Properties Company	03-16-2006
wo	2006/028545	A2	3M Innovative Properties Company	03-16-2006
WO	2006/028962	A2	3M Innovative Properties Company	03-16-2006
WO	2006/029115	A2	3M Innovative Properties Company	03-16-2006
WO	2006/031878	A2	Novartis Vaccines And Diagnostics Inc.	03-23-2006
WO	2006/038923	A2	3M Innovative Properties Company	04-13-2006
	WO	WO 2005/123079 WO 2005/123080 WO 2006/09832 WO 2006/09832 WO 2006/026760 WO 2006/028545 WO 2006/028545 WO 2006/028545 WO 2006/02815 WO 2006/02815 WO 2006/031878	WO 2005/123079 A2 WO 2005/123080 A2 WO 2006/09826 A1 WO 2006/09832 A1 WO 2006/026760 A2 WO 2006/028451 A1 WO 2006/028545 A2 WO 2006/028545 A2 WO 2006/028762 A2 WO 2006/03878 A2	WO 2005/123079 A2 3M Innovative Properties Company WO 2005/123080 A2 3M Innovative Properties Company WO 2006/009826 A1 3M Innovative Properties Company WO 2006/009832 A1 3M Innovative Properties Company WO 2006/028451 A1 3M Innovative Properties Company WO 2006/028845 A2 3M Innovative Properties Company WO 2006/028962 A2 3M Innovative Properties Company WO 2006/029115 A2 3M Innovative Properties Company WO 2006/031878 A2 Novartis Vaccines And Diagnostics Inc.

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials *	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		Supplementary European Search Report for 04782492.5 mailed January 28, 2009 (C1271.70021EP00).	
		International Search Report and Written Opinion for PCT/US2004/028021 mailed February 3, 2005 (C1271.70021WO00).	
		International Preliminary Report on Patentability for PCT/US2004/028021 mailed February 27, 2006 (C1271.70021WO00).	
		Office Communication mailed September 15, 2008 for Application No. 10/595,103 (C1271.70021US02).	
		Office Communication mailed June 17, 2009 for Application No. 10/595,103 (C1271.70021US02).	
		Notice of Allowance mailed December 30, 2009 for Application No. 10/595,103 (C1271.70021US02).	
		Notice of Allowance mailed April 16, 2010 for Application No. 10/595,103 (C1271.70021US02).	
		GIANNI et al., Influence of the Mucosal Epithelium Microenvironment on Langerhans Cells: Implications for the Development of Squamous Intraepithelial Lesions of the Cervix. Int J Cancer. 2002;97:654:659	

[NOTE.—No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stood in the USPTO's Images File Wrapper (IFW) system, are included. See a 7C FR § 1.98 and 12570G163. Copies of all other patenticity, publications, pending U.S. patent applications, or other information listed are provided as required by 37 CFR § 1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR § 1.98, and 2) the earlier application is relied upon for an earlier filling date under 35 U.S.C.§ 1.98.

EXAMINER:	DATE CONSIDERED:

^d EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.